The Protocol Review and Monitoring System (PRMS) continues to have as its major goal the assurance of the quality of the clinicaL research at the M.D. Anderson Cancer Center. PRMS consists of three major elements. Fist, the Clinical Research Committee and Psychosocial, Behavioral and Health Services Research Committee review the scientific aspects of protocols. This review includes the determination of validity of the scientific question, the appropriateness of the design of the study, the applicability of the proposed biostatistical methods of analysis, and the feasibility of the study reaching its state objectives. Second, the Protocol Data Management System (PDMS) must be used to register all patients of clinical trials. An eligibility checklist must be successfully completed prior to patient registration and release of drug from the pharmacy. Thus, a single database now exists in which clinical trials patient information is deposited for review and audit. Third, the Office of Clinical Research Quality Assurance audits the performance of the trial with the approved protocol and the agreement of the PDMS database with the patient record (two random audits per month). Thus, critical elements of the Clinical Trials Support Resource Core constitute the various checkpoints for PRMS process. Protocol prioritization remains the responsibility of the clinical departments. This is because the major expertise for prioritization of disease-specific protocols resides in these departments. However, the committees reviewing the scientific of proposals can disapprove or make approval contingent upon appropriate prioritization of protocols at any time during the review process. Further, the Office of Clinical Research Quality Assurance has received investigators' requests to close over 100 protocols following a detailed review of accrual done by that office. This is a regular, on-going activity of this office (every 6 months). Using this three-part system, we have developed a PRMS that assures the highest standards of peer-reviewed clinical research, a system of random audits, and an institution-wide database that allows auditing and data monitoring functions to occur rapidly and with minimal disruption to on- going work.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-26S2
Application #
6506691
Study Section
Project Start
2001-09-28
Project End
2002-06-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications